Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | unknown | — |
The patient received only two doses of RabAvert; Case reference number US-BN-2025-000985 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV25-1164) on 20-May-2025 and concerns a patient of unspecified age and gender. The patient's medical history and concomitant medication details were not provided. On unspecified date in 2022, the patient received two doses of RabAvert vaccine along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown) at unknown dose, route or site of administration for indication pre-exposure. As reported the patient received only two doses (explicitly coded as 'incomplete course of vaccination'). At the time of initial report, it was unknown if patient experienced any of adverse events due to RabAvert. No further information was provided.; Reporter's Comments: This case report concerns a patient of unspecified age and gender. Reportedly, the patient received only two doses of RabAvert which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if patient experienced any of adverse events due to RabAvert. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.; Sender's Comments: This case report concerns a patient of unspecified age and gender. Reportedly, the patient received only two doses of RabAvert which is considered as incomplete course of vaccination. Incomplete course of vaccination is considered listed per company convention. The patient's medical history and concomitant medication details were not provided. At this point, it was unknown if patient experienced any of adverse events due to RabAvert. Causality is assessed as not related to suspect product but to human factor. The case is non-serious.
Comments: NONE